World Hepatitis Day calls for efforts to eliminate hepatitis by 2030
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
The U.S. Food and Drug Administration (FDA) has approved Vir Biotechnology’s request to conduct clinical testing in the U.S. of a combination of two investigational…
Levels of neurotensin, a small protein highly present in the gastrointestinal tract, are higher than normal in the blood and liver of biliary atresia…
A noninvasive test that detects a fluorescent dye in stools could help doctors make a biliary atresia diagnosis faster than current methods, distinguishing the…
The levels of more than 250 proteins are abnormal in lab-grown liver organoids, or mini-livers, derived from a mouse model of progressive familial intrahepatic…
LISCure Biosciences will launch a Phase 2 trial in the United States to evaluate the safety and effectiveness of LB-P8, its live bacterium candidate…
The U.S. Food and Drug Administration (FDA) has granted fast track status to bepirovirsen, GlaxoSmithKline (GSK)’s candidate treatment for chronic hepatitis B (CHB),…
The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase…
NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.